Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cytokinetics ( (CYTK) ).
On August 19, 2025, Cytokinetics appointed James M. Daly to its Board of Directors as a Class III member, with his term expiring in 2028. Mr. Daly, determined to be independent under corporate governance guidelines, will also serve on the Compliance Committee and participate in the company’s non-employee director compensation arrangements, including stock options and restricted stock units.
The most recent analyst rating on (CYTK) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.
Spark’s Take on CYTK Stock
According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.
Cytokinetics’ overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative equity. While technical analysis shows positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with regulatory progress and sales force readiness, but financial challenges and delays in drug approval timelines remain significant concerns.
To see Spark’s full report on CYTK stock, click here.
More about Cytokinetics
Cytokinetics, Incorporated operates in the biopharmaceutical industry, focusing on the development and commercialization of muscle biology-driven treatments for debilitating diseases. The company primarily targets conditions related to muscle function and performance.
Average Trading Volume: 1,449,302
Technical Sentiment Signal: Hold
Current Market Cap: $4.66B
See more insights into CYTK stock on TipRanks’ Stock Analysis page.